Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Effetto della vitamina B2 erogata dal colon sul microbiota intestinale e sui relativi biomarcatori di salute negli anziani sani

6 novembre 2026 aggiornato da: dsm-firmenich Switzerland AG

The goal of this intervention study (clinical trial) is to investigate the effect of colon-delivered Riboflavin (vitamin B2) on the faecal microbial composition and diversity in older healthy subjects (50 -70 years of age)

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

348

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Cork, Irlanda
        • Atlantia Food Clinical Trials, 1st Floor, Block C, Heron House, Blackpool Retail Park, Cork

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 50 anni a 70 anni (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Participants must be willing and able to give written informed consent and to understand, to participate, and to comply with the clinical study requirements.
  2. Between 50 and 70 years of age.
  3. Has a BMI of between 18.5 - 30 Kg/m2.
  4. Participants have had a stable body weight (≤5 % change) over the past 3-months.
  5. Is in general good health, as determined by interview and vital signs (blood pressure, heart rate, pulse) by the investigator.
  6. Willing to avoid consuming gut microbiome modulating dietary supplements, prebiotic, probiotic, or fibre-rich supplements, and, within 4 weeks prior to the baseline visit, until the end of the study.
  7. Maintain current level of physical activity.
  8. Willing to consume the investigational product daily for the duration of the study.
  9. Female participants in menopause for at least the last one year. -

Exclusion Criteria:

  1. Are hypersensitive to any of the components of the test product.

  2. Has taken antibiotics within the previous 3 months prior to Baseline (Visit2)

  3. Is currently using systemic steroids, systemic antibiotics, proton pump inhibitors, H2 blocker, antacid, metformin, or immunosuppressant medication.

  4. Participant has a history of drug and/or alcohol abuse at the time of enrolment (Drinks more than nationally recommended units per week (>11 units for women; >17 units for men); Is currently in treatment for alcohol/substance abuse; Has been diagnosed with alcohol/substance abuse disorder).

  5. Is a smoker or vaper.

  6. Vegetarian or vegan.

  7. Has made any major dietary changes in the past 3 months prior to Baseline (Visit 2).

  8. Planned major changes in the lifestyle (i.e., diet, dieting, exercise level, significant travel) during the duration of the study.

  9. Has a currently active eating disorder.

  10. Has food allergies or other issues with foods that would preclude the intake of the study products, as determined by the study investigator.

  11. Is having a typical fibre intake >30 g fibre/day.

  12. Has an active gastrointestinal disorder or previous gastrointestinal surgery, which in the opinion of the investigator would impact the study outcomes.

  13. If taking chronic medications (e.g., anti-hypertensive medications), they must have been taking the product for at least two months to screening and agree to maintain the same dosage throughout the study.

  14. Has severe or uncontrolled type 2 diabetes, psychiatric disorder, gastrointestinal disease (i.e., diarrhoea, Crohn's disease, ulcerative colitis, IBS, diverticulosis, stomach or duodenal ulcers respiratory or cardiac illness or any other condition which in the opinion of the investigator would impact the study outcomes.

  15. Has a current or history of any gastrointestinal cancer

  16. Are severely immunocompromised (HIV positive, transplant patient, on anti-rejection medications, on a steroid for >30 days, or chemotherapy or radiotherapy with the last year).

  17. Experiences alarm features such as weight loss, rectal bleeding, a recent change in bowel habit (<3 months).

  18. Have a current malignant disease or any concomitant end-stage organ disease.

  19. Individuals who, in the opinion of the investigator are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.

  20. Participants may not be receiving treatment involving experimental drugs. If the participant has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.

  21. Participants who have undergone intensive skin treatments (e.g. laser treatment or skin related surgery) in the last 3 months.

  22. If taking any dietary supplements or medications known to affect skin health or other trial measures (resveratrol, ginkgo biloba, ginseng, fruit powder extracts and DHA).

  23. Has a skin condition likely to interfere with skin assessments (e.g., eczema, dermatitis, any open skin wounds, reactive and sensitive skin).

    -

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Low dose

Daily dose of 1.4 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Sperimentale: Mid dose

Daily dose of 10 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Sperimentale: high dose

Daily dose of 75 mg Vitamin B2 (Riboflavin) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Comparatore placebo: Placebo

One capsule of 570 mg (consisting of microcrystalline cellulose) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Faecal microbial composition
Lasso di tempo: from baseline to 12 weeks

Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 12

from baseline to 12 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Alpha diversity
Lasso di tempo: from baseline to 12 weeks

Alpha diversity (Observed, Chao Index, Simpson Index, Shannon Index) at baseline and week 12.

from baseline to 12 weeks
Beta diversity
Lasso di tempo: week 0 to week 12

Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 12

week 0 to week 12
Faecal microbial metabolites fatty acid content at baseline and week 12
Lasso di tempo: from baseline to 12 weeks

Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 12

from baseline to 12 weeks
Acetate, Propionate and Butyrate
Lasso di tempo: baseline and week 12

Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 12.

baseline and week 12
Intestinal inflammation
Lasso di tempo: from baseline to 12 weeks

Intestinal barrier integrity as assessed by sCD14 at baseline and at week 12

from baseline to 12 weeks
Intestinal barrier integrity
Lasso di tempo: from baseline to 12 weeks

Oxidative stress level measured as free thiol content in blood at baseline and at week 12

from baseline to 12 weeks
Oxidative stress in blood
Lasso di tempo: from baseline to 12 weeks

Oxidative stress level measured as free thiol content in blood at baseline and at week 12

from baseline to 12 weeks
Inflammatory status in blood
Lasso di tempo: from baseline to 12 weeks

Systemic inflammation measured as high sensitive C reactive protein (hs-CRP) in blood at baseline and at week 12.

from baseline to 12 weeks
Gastrointestinal symptoms
Lasso di tempo: from baseline to 12 weeks

Gastrointestinal symptoms as assessed by Gastrointestinal Symptom Rating Scale (GSRS).The GSRS is a 15 items questionnaire combined into five symptom clusters i.e Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.(GSRS) at baseline and at week 12.

from baseline to 12 weeks
health-related quality of life
Lasso di tempo: from baseline to 12 weeks

Quality of life as assessed by short form survey-36 (SF-36) questionnaires at baseline and at week 12.

The SF-36 is a self-administered questionnaire comprising 36-items measuring eight health domains: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). These outcomes will be grouped as a physical component summary and a mental component summary. The norm data is 0-100, and the health-related quality of life increases as the scores increase.

from baseline to 12 weeks
Stool consistency
Lasso di tempo: from baseline to 12 weeks

Stool consistency (Bristol Stool Scale), as reported in the daily eDiary app (at baseline and week 12).

Participants will identify each bowel movement 'type' using the Bristol Stool Scale (Type 1 = hard stool difficult to pass [classified as severe constipation]; Type 7 = watery, entirely liquid stool [classified as severe diarrhea]). 'Normal' stool is considered to be Types 3 and 4; and Types 6 and 7 would be considered to suggest mild and severe diarrhea, respectively.

from baseline to 12 weeks
Stool frequency
Lasso di tempo: from baseline to 12 weeks

Stool frequency, as reported in the daily eDiary app (at baseline and week 12).

from baseline to 12 weeks
Systemic vitamin status
Lasso di tempo: from baseline to 12 weeks

The concentration of B vitamins in blood at baseline

from baseline to 12 weeks
Faecal physiological pH and redox
Lasso di tempo: from baseline to 12 weeks

Faecal physiological parameters measured as pH and redox potential at baseline and at week 12.

from baseline to 12 weeks
Faecal microbial composition at week 4
Lasso di tempo: from baseline to 4 weeks

Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 4.

from baseline to 4 weeks
Alpha diversity at week 4
Lasso di tempo: baseline to Week 4.

Alpha diversity measured as Observed, Chao Index, Simpson Index, Shannon Index at baseline and Week 4.

baseline to Week 4.
Beta diversity at week 4
Lasso di tempo: week 0 to week 4

Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 4

week 0 to week 4
Microbial metabolites at week 4
Lasso di tempo: from baseline to 4 weeks

Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 4.

from baseline to 4 weeks
Acetate, Propionate and Butyrate at week 4
Lasso di tempo: week 0 to week 4

Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 4.

week 0 to week 4

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Skin barrier integrity
Lasso di tempo: from baseline to 12 weeks

Skin barrier integrity measured as trans-epidermal water loss (TEWL) g/m²/h at baseline and at week 12.

from baseline to 12 weeks
Skin hydration
Lasso di tempo: from baseline to 12 weeks

Skin hydration measured using corneometry from 0 (no water at all) to 120 (on water) at baseline and at week 12.

from baseline to 12 weeks
Objective skin-health
Lasso di tempo: from baseline to 12 weeks

Objective skin-health assessment completed by the participant using Likert scale (from not at al to very much) at baseline and at week 12.

from baseline to 12 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Prof Timothy Dinan, Cork University Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

12 dicembre 2022

Completamento primario (Effettivo)

6 luglio 2023

Completamento dello studio (Effettivo)

6 luglio 2023

Date di iscrizione allo studio

Primo inviato

16 febbraio 2023

Primo inviato che soddisfa i criteri di controllo qualità

27 marzo 2023

Primo Inserito (Effettivo)

7 aprile 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

1 settembre 2023

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2020-11-11-VITB2

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .